Skip to main content
Log in

Interaction of sulphinpyrazone with warfarin

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The effect of sulphinpyrazone administration on the anticoagulant response was investigated in five patients receiving long-term treatment with warfarin. Sulphinpyrazone caused a rapid increase in prothrombin (PT) ratio in all five patients and warfarin dose had to be reduced by a mean of 46% to maintain the PT ratio in the therapeutic range. PT ratio and daily warfarin requirement returned to previous levels when sulphinpyrazone was ceased. Warfarin protein binding was not altered during sulphinpyrazone administration and sulphinpyrazone added to plasma in vitro did not increase warfarin free fraction. The average racemic plasma warfarin concentration over a dosage interval when adjusted for warfarin dose was not altered by sulphinpyrazone administration. The most likely mechanism for this drug interaction is a stereoselective effect of sulphinpyrazone on the metabolism of the warfarin enantiomers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ali M, McDonald JWD (1977) Effects of sulphinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. J Lab Clin Med 89: 868–875

    Google Scholar 

  2. Kaegi A, Pineo GF, Shimizu A, Trivedi H, Hirsh J, Gent M (1975) The role of sulphinpyrazone in the prevention of arteriovenous shunt thrombosis. Circulation 52: 497–499

    Google Scholar 

  3. Steele P, Rainwater J, Vogel R, Genton E (1978) Platelet suppressant therapy in patients with coronary artery disease. J Am Med Assoc 240: 228–231

    Google Scholar 

  4. Steele P, Rainwater J (1980) Favourable effect of sulphinpyrazone on thromboembolism in patients with rheumatic heart disease. Circulation 62: 462–465

    Google Scholar 

  5. Altman R, Boullon F, Rouvier J, Raca R, de la Fuente L, Favaloro R (1976) Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg 72: 127–129

    Google Scholar 

  6. Dale J, Myhre E, Storstein O, Stormorken H, Efskind L (1977) Prevention of arterial thromboembolism with acetylsalicylic acid. Heart 94: 101–111

    Google Scholar 

  7. Sullivan JM, Harken JE, Gorlin R (1971) Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med 284: 289–295

    Google Scholar 

  8. Bailey RR, Reddy J (1980) Potentiation of warfarin action by sulphinpyrazone. Lancet 1: 254

    Google Scholar 

  9. Davis JW, Johns LE (1978) Possible interaction of sulphinpyrazone with coumarins. N Engl J Med 299: 955

    Google Scholar 

  10. Mattingley D, Bradley M, Selley PJ (1978) Hazards of sulphinpyrazone. Br Med J 2: 1786–1787

    Google Scholar 

  11. Thompson PL, Serjeant C (1981) Potentially serious interaction of warfarin with sulphinpyrazone. Med J Aust 1: 41

    Google Scholar 

  12. Weiss M (1979) Potentiation of coumarin effect by sulphinpyrazone. Lancet 1: 609

    Google Scholar 

  13. Gallus A, Birkett DJ (1980) Sulphinpyrazone and warfarin: a probable drug interaction. Lancet 1: 535–536

    Google Scholar 

  14. Bjornsson TD, Blaschke TF, Meffin PJ (1977) High pressure liquid chromatographic analysis of drugs in biological fluids: Part I. Warfarin. J Pharm Sci 66: 142–144

    Google Scholar 

  15. Wong LT, Solomonraj G, Thomas BH (1978) Simple and rapid microdetermination of sulphinpyrazone in biological fluids by reversed-phase high performance chromatography. J Chromatogr 150: 521–526

    Google Scholar 

  16. Duncombe WG (1964) The colorimetric microdetermination of non-esterified fatty acids in plasma. Clin Chim Acta 9: 122–125

    Google Scholar 

  17. Birkett DJ, Meffin PJ, Wing LMH (1979) Fundamentals of Clinical Pharmacology 6. Plasma Protein Binding. Curr Ther 20: 89–99

    Google Scholar 

  18. Sellers EM (1979) The clinical importance of interactions based on displacement of protein bound drugs, in Tillement JP, editor: Advances in pharmacology and therapeutics, vol. 7 from: Biochemical clinical pharmacology. Pergamon Press, New York, pp 153–162

    Google Scholar 

  19. Lewis RJ, Trager WF, Chan KF, Breckenridge A, Orme M, Roland M, Schary W (1974) Warfarin: Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 53: 1607–1617

    Google Scholar 

  20. O'Reilly RA, Trager WF, Motley CH, Howald W (1980) Stereoselective interaction of phenylbutazone with [12C/13C] warfarin pseudoracemates in man. J Clin Invest 65: 746–753

    Google Scholar 

  21. O'Reilly RA (1976) The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 295: 354–357

    Google Scholar 

  22. O'Reilly RA (1980) Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med 302: 33–35

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miners, J.O., Foenander, T., Wanwimolruk, S. et al. Interaction of sulphinpyrazone with warfarin. Eur J Clin Pharmacol 22, 327–331 (1982). https://doi.org/10.1007/BF00548401

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00548401

Key words

Navigation